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Abstract
Background: Fabry-associated pain may be the first symptom of Fabry disease (FD) and presents with a unique
phenotype including mostly acral burning triggerable pain attacks, evoked pain, pain crises, and permanent pain.
We recently developed and validated the first Fabry Pain Questionnaire (FPQ) for adult patients. Here we report on
the validation of the self-administered version of the FPQ that no longer requires a face-to-face interview but can
be filled in by the patients themselves allowing more flexible data collection.
Methods: At our Würzburg Fabry Center for Interdisciplinary Treatment, Germany, we have developed the
self-administered version of the FPQ by adapting the questionnaire to a self-report version. To do this, consecutive
Fabry patients with current or past pain history (n = 56) were first interviewed face-to-face. Two weeks later
patients’ self-reported questionnaire results were collected by mail (n = 55). We validated the self-administered
version of the FPQ by assessing the inter-rater reliability agreement of scores obtained by supervised administration
and self-administration of the FPQ.
Results: The FPQ contains 15 questions on the different pain phenotypes, on pain development during life with and
without therapy, and on impairment due to pain. Statistical analysis showed that the majority of questions were
answered in high agreement in both sessions with a mean AC1-statistic of 0.857 for 55 nominal-scaled items and
a mean ICC of 0.587 for 9 scores.
Conclusions: This self-administered version of the first pain questionnaire for adult Fabry patients is a useful tool
to assess Fabry-associated pain without a time-consuming face-to-face interview but via a self-reporting survey
allowing more flexible usage.
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Background
The X-linked lysosomal storage disorder Fabry disease
(FD) is caused by mutations in the encoding gene of the
α-galactosidase A (α-GAL), which lead to reduction or
complete loss of enzyme activity. The consequence is the
accumulation of the sphingolipid globotriaosylceramide-3
(Gb3) particularly in kidneys, heart, and the nervous sys-
tem [1]. The only treatment option currently available is
enzyme replacement therapy (ERT).
Patients with FD frequently suffer from pain that
mostly starts in early childhood [2, 3]. Often small fiber
neuropathy is associated with FD and may contribute to
Fabry-associated pain [4–8, 3]. Fabry-associated pain is
of a distinct phenotype mostly leading to episodic acral
burning pain attacks, evoked pain, and pain crises; to a
lesser extent permanent pain may be present [3]. We re-
cently developed and validated the first Fabry Pain Ques-
tionnaire (FPQ) for adult patients [9]. The FPQ is
designed for a face-to-face interview and covers ques-
tions on Fabry specific pain characteristics. To allow
pain assessment in Fabry patients without personal re-
port at a referral Fabry Center we developed and vali-
dated the self-reporting version of the FPQ.
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Methods
Development of the self-administered version of the FPQ
Our study was approved by the Ethics Committee of the
Medical Faculty of the University of Würzburg (#25/13),
and written informed consent was obtained before inclu-
sion from every study participant. On the basis of the re-
cently validated face-to-face version of the FPQ [9] we
first adapted the introductory parts of its 15 questions to
a more explanatory version (NÜ, BM, CS) allowing pa-
tients to understand and answer the questions without
the oral instructions of an interviewer. This first version
was reviewed and revised (SW, PH) before the self-
administered FPQ (saFPQ) was then validated. In brief,
the FPQ assesses the four Fabry-associated pain pheno-
types (pain attacks, evoked pain, pain crises, permanent
pain) in childhood and adulthood with regard to pain
presence, localization (including a pain drawing), fre-
quency, qualities, triggers, and development over time
with and without ERT and symptomatic treatment. Add-
itionally, patients are asked about pain-associated im-
pairment at work and during everyday life.
Study design
From July 2014 to February 2015 study participants
were first interviewed face-to-face with the saFPQ by
a trained interviewer (BM) during their visit at our
Fabry Center for Interdisciplinary Treatment (FAZIT)
or were visited at their homes. The questions were
read out to the patient, and the individual answers
and the time necessary to complete the questionnaire
were noted. Patients were then asked to individually fill in
the questionnaire again two weeks later at their homes
and to send back the questionnaire by mail. Patients also
noted the time needed to complete the questionnaire.
Patients
The following inclusion criteria were applied for the
study cohort: ≥18 year old men or women with genetic-
ally proven FD; current and/or past pain history. Patients
were recruited at FAZIT in Germany, which is a tertiary
referral center. Patients had previously not taken part in
the evaluation of the FPQ [9].
Statistical analysis
All analyses were performed using IBM SPSS Version
22 (Ehningen, Germany) and SAS, version 9.3 (SAS
Institute Inc, Cary, NC, USA). According to previous
studies [10] and with regard to the number of pa-
tients seen at FAZIT, the number of available and
suitable cases was calculated. Of the approximately
220 Fabry patients known at our Center 60-70 % of
patients do and/or did suffer from pain in adulthood
and/or childhood. Of these patients 62 had already
been interviewed during the validation of the face-to-
face version of the FPQ [9]. In order to control for the in-
fluence of current pain intensity on how patients an-
swered the questions in the two sessions, we a priori
defined that analyses would be restricted to patients
who reported identical current pain intensities at both
sessions, defined as a deviation of ≤1 point on a nu-
meric rating scale (NRS) for question 6 of the FPQ. For
a detailed description of the statistical analysis per-
formed see Additional file 1.
Results
Study cohort
Table 1 summarizes demographic data of the study par-
ticipants. Fifty-six Fabry patients of the FAZIT fulfilling
the inclusion criteria were enrolled. Of these, 55 pa-
tients received a first face-to-face interview and two
weeks later filled in and sent back the saFPQ. One pa-
tient did not fill in and/or send back the questionnaire
and was lost to follow-up. 15 patients were excluded
because they reported varying current pain intensities
on question 6 of the FPQ. Finally, the study cohort con-
sisted of 40 Fabry patients (22 men, 18 women; median
age: 42 years, range 21 to 67 years). None of the pa-
tients reported pain only in childhood while 34/40
(85 %) patients had pain in childhood and adulthood;
6/40 (15 %) patients reported pain only in adulthood.
With regard to the current pain phenotypes, 36/40
(90 %) patients reported pain attacks, 32/40 (80 %) had
pain crises, 27/40 (68 %) suffered from evoked pain,
and 18/40 (45 %) had permanent pain.
Face-validity
All saFPQ items were answered completely by all study
participants. The overall acceptance by the patients was
high and patients gave a very positive feedback about the
content and the format of the questions. The median
time necessary to fill in the saFPQ during the face-to-
face interview was 15 min (range 10–20 min), and dur-
ing the self-filling-in period 15 min (range 10–30 min).
Table 1 Demographic data of the study population
Number of patients (N) 40
M, F (N) 22, 18
Median age (range) 42 (21–67)
Pain only in childhood (M/F) none
Pain only in adulthood (M/F) 6 (0/6)
Pain in childhood and adulthood (M/F) 34 (22/12)
Shows demographic data of the study population and numbers of patients
with pain only in childhood/adulthood or in childhood as well as in adulthood.
M =Male, F = Female
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Assessing inter-rater reliability for the self-administered
and the face-to-face version
Agreement between the self-administered and the face-to-
face version was very high for nominal-scaled items with a
mean of all AC1-statistics of 0.857 (range 0.580-1.000).
With the exception of evoked pain by contact (4a), all
items of questions 1–5 (referring to the four major pain
phenotypes and sensitivity impairment) showed good
agreement with AC1-statistics (≥0.600; Table 2). Ques-
tion 8 (pain location) had very good agreement with
AC1-statistics (≥0.800 for all items; Table 2). Assessing
agreement of question 10 (last pain event), we had the
problem that most of the patients had one or more pain
events between the two sessions of interview/self-report
and therefore answered the question differently. Thus,
we only analyzed 11 patients with no pain in the mean-
time, with a good AC1-statistics result (Table 2). Pain
quality reported by patients in question 11 showed high
agreement across all items, with only two AC1-statistics
between 0.600 and 0.800 and the other ones having values
of ≥0.800 (Table 2). Results for questions 12 (pain triggers)
and 13 (impairment at work due to pain) also showed high
agreement (Table 2). Regarding the scored items of the
questionnaire, questions 7a and 7b (pain frequency) had
poor inter-rater reliability, while the other questions
reached good inter-rater reliability with ICCs from 0.577
to 0.970 (Table 2). For question 7b, all patients without
ERT were excluded from analysis with 22 patients
remaining. The mean ICC for the interval-scaled items
was 0.587. No assessment of agreement was performed
for free text questions 2a, 3a and 9. The final German
version of the saFPQ is provided in the supplement sec-
tion (Additional file 2). A first, not yet formally vali-
dated English translation is also added (Additional file 3).
Discussion
We present the self-administered version of the first
pain questionnaire for adult Fabry patients which is
based on the published face-to-face interview version
[9]. This self-administered version allows pain assess-
ment and follow-up also in patients that are not able to
personally come to their referral Fabry Center. Add-
itionally, the saFPQ reduces evaluation time of the
treating physician in clinical practice due to its self-
reporting nature.
Recently, a pain questionnaire as part of a data collec-
tion on Fabry symptoms and items was published to be
used in children with FD [11]. FPQ was the first pain
questionnaire for adult Fabry patients [9] covering all
relevant items of this very special pain phenotype instead
of asking about few and selected pain characteristics
only [12]. Based on our longstanding experience with
Fabry-associated pain at one of the largest German Fabry
centers, FPQ helps obtaining data on current and
childhood Fabry-associated pain in a standardized manner
[9]; it fills a gap where standardized pain questionnaires
fail to properly reflect Fabry-associated pain [13, 3, 14].
Since its publication FPQ has been used routinely at
the FAZIT allowing comprehensive patient assessment
and data collection. Patients’ feedback is very positive
and further German Fabry Centers have started applying
FPQ in their clinical routine. Particularly, the inclusion
of the FPQ as an assessment tool for data collection in
multi-center and large scale studies and in Fabry regis-
tries is warranted (personal communication). However,
in its original version with a face-to-face interview de-
sign the FPQ was unpractical and time-consuming for
the treating physicians. To overcome this drawback we
have now designed and validated the self-administered
version of the FPQ that allows the assessment of Fabry
patients in a self-reporting manner and even if they can-
not personally come to the referral Fabry Center.
One limitation of our study is the relatively low num-
ber of subjects, however, the statistical analysis of the
saFPQ showed that the majority of questions have a
good to very good test-retest-reliability. Few questions
were obviously difficult to answer in the study setting
with two time points and potential events in between
like question 7: “How did your pain (with or without
treatment) develop since last visit ?” Some patient re-
ferred to the last visit two weeks ago (i.e., to the time
point of the face-to-face interview) and some patients
referred to their last regular visit at the FAZIT one year
ago. This, however, is due to the special study situation
with two consecutive interviews, which is not clinical
routine and therefore without practical relevance. One
reason why some patients may have given inconsistent
answers to some of the questions at the two sessions
may be that particularly patients with low-frequent epi-
sodic pain do not see this (manageable) pain as a major
problem and therefore judge changes less consistently
when asked at two different time points. Another rea-
son for the inconsistent answers particularly with regard
to the analgesic effect of ERT may be based on the experi-
ences patients made during ERT supply shortage (http://
www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/
UCM187056.pdf). During this period not only ERT dos-
age but also the compound (agalsidase-beta switch to
agalsidase-alpha) was changed in some patients. It may
have been difficult for these patients to judge if any
changes in their pain during this phase were due to
changes in ERT dosage or compound, or whether this
was part of the natural course of their disease. Another
aspect that needs to be taken into account are the
known alterations in cognitive function of Fabry pa-
tients [15]. These may influence consistent replies on
repetitively asked questions, which is also a known
phenomenon in clinical routine e.g., during history
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Table 2 Results of statistical analysis on test-retest reliability of the FPQ questions
saFPQ question AC1-statistic (95 % confidence interval) Scale Statistics
1) Do you have permanent pain in adulthood or did you have permanent pain in childhood? Adulthood: 0.901 (0.766–1) Nominal AC1
Childhood: 0.834 (0.697–0.971)
2) Do you have pain attacks in adulthood or did you have pain attacks in childhood? Adulthood: 0.939 (0.855–1) Nominal AC1
Childhood: 0.875 (0.757–0.993)
2a) If you have pain attacks in adulthood or if you had pain attacks in childhood: how often
did/how often do these pain attacks occur and for how long did/how long do these pain
attacks last?
No statistics
3) Do you have pain crises in adulthood or did you have pain crises in childhood? Adulthood: 0.714 (0.520–0.908) Nominal AC1
Childhood: 0.801 (0.652–0.950)
3a) If you have pain crisis in adulthood or if you had pain crisis in childhood: how frequent
were/are these pain crises and how long did/do they last in average?
No statistics
4a) Do you have in adulthood or did you have in childhood pain that can be triggered
by touch?
Adulthood: 0.593 (0.356–0.830) Nominal AC1
Childhood: 0.580 (0.390–0.770)
4b) Do you have in adulthood or did you have in childhood pain that can be triggered by a
cold object?
Adulthood: 0.730 (0.559–0.901) Nominal AC1
Childhood: 0.688 (0.506–0.870)
4c) Do you have in adulthood or did you have in childhood pain that can be triggered by a
warm object?
Adulthood: 0.800 (0.651–0.949) Nominal AC1
Childhood: 0.663 (0.479–0.847)
4d) Do you have in adulthood or did you have in childhood pain that can be triggered by
pressure?
Adulthood: 0.817 (0.645–0.989) Nominal AC1
Childhood: 0.767 (0.608–0.926)
5) Do you have in adulthood or did you have in childhood sensory impairment like numbness
or tingling in the painful body area?
Adulthood: 0.742 (0.579–0.905) Nominal AC1
Childhood: 0.688 (0.517–0.859)
6) What is your pain intensity at the moment?a 0.970 (0.945–0.984) Interval ICC
7) How did your pain develop over time (with or without treatment)? Frequency: 0.400 (0.103–0.632) Interval ICC
7a) Since last visit in Würzburg Intensity: 0.173 (−0.145–0.459)
7) How did your pain develop over time (with or without treatment)? Frequency: 0.123 (−0.299–0.508) Interval ICC
7b) Under enzyme replacement therapy Intensity: 0.577 (0.222–0.798)
7) How did your pain develop over time (with or without treatment)? Frequency: 0.902 (0.819–0.948) Interval ICC
7c) During life Intensity: 0.764 (0.592–0.869)









9) Which analgesic drugs do you take? No statistics
10) When was the last time you had pain? No statistics
10a) What type of pain was your last pain? 0.889 (0.671–1) Nominal AC1
10b) The last time you had pain: what was its maximum intensity on a scale from zero
to ten?
0.875 (0.630–1) Nominal AC1
10c) The last time you had pain: what was its average intensity on a scale from zero
to ten?
0.620 (0.236–1) Nominal AC1
11) How does your pain feel? Adulthood burning: 0.902 (0.794–1) Nominal AC1
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taking. Since the main aim of our study was to investi-
gate questionnaire reliability, we did not compare our
questionnaire with other tools such as the Brief Pain
Inventory (BPI). The BPI does not contain Fabry-
associated questions, but has been applied in large co-
horts of FD patients e.g., in the Fabry registries.
In the setting of a rare disease, it is not feasible that
patients travel to the referral Fabry Center for any
change in symptoms. To still be able to obtain standard-
ized data, the saFPQ will be a useful tool. This may be
of particular relevance during clinical trials when pa-
tients need to apply self-report instruments between











Adulthood like electric shocks: 0.644
(0.420–0.867)
Childhood like electric shocks: 0.840
(0.689–0.991)
Adulthood tearing: 0.915 (0.821–1)
Childhood tearing: 0.919 (0.831–1)
Adulthood don’t know: 1 (−)
Childhood don’t know: 0.945 (0.871–1)
12) Are there triggers for your pain? Adulthood without trigger: 0.751
(0.545–0.957)
Nominal AC1
Childhood without trigger: 0.873
(0.734–1)
Adulthood heat: 0.917 (0.803–1)
Childhood heat: 0.951 (0.855–1)
Adulthood cold: 0.901 (0.766–1)
Childhood cold: 0.864 (0.715–1)
Adulthood fever: 1 (−)
Childhood fever: 1 (−)
Adulthood physical activity: 0.877
(0.742–1)
Childhood physical activity: 0.95
(0.854–1)
Adulthood sports: 1 (−)
Childhood sports: 1 (−)
Adulthood don’t know: 1 (−)
Childhood don’t know: 1 (−)
13) How many days without work (including housework) did you have in the last year
due to pain?
0.967 (0.902–1) Nominal AC1
14) How much does pain influence your working ability (including housework) in general
on a scale from zero to ten?
0.693 (0.491–0.825) Interval ICC
15) How much does pain influence your leisure activities in general on a scale from zero
to ten?
0.680 (0.472–0.816) Interval ICC
Table 2 gives details on data scales and the statistics used for each saFPQ item
AC1, ICC, saFPQ self-administered Fabry Pain Questionnaire
aOnly patients with a difference ≤1 point included in analysis
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visits. Now pain data from Fabry patients (for clinical
practice and trials) can even be obtained in remote areas
where only few or no Fabry Centers are present. Thus,
saFPQ brings further flexibility to the assessment of
Fabry-associated pain. The next step will be to validate
the English version of the saFPQ to make the question-
naire available for even more Fabry patients.
Conclusion
Fabry-associated pain is distinct in phenotype and needs
special tools for standardized assessment during clinical
practice and in trials. The saFPQ is the first self-
administered pain questionnaire designed for Fabry patients
and will substantially improve pain management and data
acquisition in patients suffering from Fabry-associated pain.
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